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Abstract: BACKGROUND/AIMS The hepatitis C virus nonstructural 3/4A protease has been shown to
cleave protein tyrosine phosphatase nonreceptor type 2 (PTPN2, also known as T cell protein tyrosine
phosphatase), thereby inducing a shift from a Th1 toward a nonantiviral Th2 immunity. Ribavirin ther-
apy reverses these effects and supports direct-acting antiviral (DAA) therapy as an immunomodulatory
compound and ultimately improves the response to DAA therapy. Here we aimed to assess whether
intrahepatic levels of PTPN2 might be used as a clinical prognostic marker for the response to DAA
therapy. METHODS Liver biopsies from hepatitis C virus-infected patients with and without cirrhosis
were immunohistochemically stained for PTPN2 and scored for staining intensity as well as percentage of
hepatocytes positive for nuclear PTPN2 localization. PTPN2 scores were correlated to sustained virologic
response after DAA therapy, viral load, serum levels of alanine aminotransferase, aspartate aminotrans-
ferase, gamma-glutamyl transferase (GGT), and the Model for End-Stage Liver Disease (MELD) score
at the time of liver biopsy. RESULTS We did not detect a difference in intrahepatic PTPN2 levels
between responders with cirrhosis, responders without cirrhosis, and nonresponders to DAA therapy.
There was no correlation between intrahepatic PTPN2 levels and viral load or clinical markers such as
liver transaminases, GGT, or the MELD score. CONCLUSION Intrahepatic PTPN2 levels assessed via
IHC staining do not represent a clinical prognostic marker for the response to DAA therapy.
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Abstract
Background/Aims: The hepatitis C virus nonstructural 3/4A 
protease has been shown to cleave protein tyrosine phos-
phatase nonreceptor type 2 (PTPN2, also known as T cell pro-
tein tyrosine phosphatase), thereby inducing a shift from a 
Th1 toward a nonantiviral Th2 immunity. Ribavirin therapy 
reverses these effects and supports direct-acting antiviral 
(DAA) therapy as an immunomodulatory compound and ul-
timately improves the response to DAA therapy. Here we 
aimed to assess whether intrahepatic levels of PTPN2 might 
be used as a clinical prognostic marker for the response to 
DAA therapy. Methods: Liver biopsies from hepatitis C virus-
infected patients with and without cirrhosis were immuno-
histochemically stained for PTPN2 and scored for staining 
intensity as well as percentage of hepatocytes positive for 
nuclear PTPN2 localization. PTPN2 scores were correlated to 
sustained virologic response after DAA therapy, viral load, 
serum levels of alanine aminotransferase, aspartate amino-
transferase, gamma-glutamyl transferase (GGT), and the 
Model for End-Stage Liver Disease (MELD) score at the time 
of liver biopsy. Results: We did not detect a difference in in-
trahepatic PTPN2 levels between responders with cirrhosis, 
responders without cirrhosis, and nonresponders to DAA 
therapy. There was no correlation between intrahepatic 
PTPN2 levels and viral load or clinical markers such as liver 
transaminases, GGT, or the MELD score. Conclusion: Intrahe-
patic PTPN2 levels assessed via IHC staining do not represent 
a clinical prognostic marker for the response to DAA therapy.
© 2020 S. Karger AG, Basel
Introduction
In the past few years, novel and very potent treatment 
options for hepatitis C virus infections (HCV), so called 
direct-acting antiviral (DAA) drugs, significantly im-
proved therapy success and prognosis of infected pa-
tients. Nevertheless, HCV infections are still an impor-
tant health problem worldwide. About 178 million adults 
worldwide are infected with HCV with an estimated an-












































































nual incidence rate of 1.7 million people per year in 2015. 
About 75–85% of newly infected individuals fail to clear 
the virus and progress to a persistent, chronic HCV infec-
tion, which usually remains asymptomatic for several 
years or even decades before eventually causing severe 
liver diseases, such as cirrhosis and hepatocellular carci-
noma [1–3]. 
This remarkable ability of HCV to persist in most in-
fected patients is in part due to the interference of virus-
encoded proteins with critical immune mechanisms of 
the host. The HCV genome encodes for a polyprotein, 
which upon translation is cleaved into 3 structural (core, 
E1, and E2) and 7 nonstructural (NS) proteins (p7, NS2, 
NS3, NS4A, NS4B, NS5A, and NS5B). All the sites within 
the NS part of the polyprotein are cleaved by the viral 
serine-protease NS3 – except for the cleavage between 
NS2 and NS3. The cofactor NS4A enhances the proteo-
lytic activity of NS3 [4, 5].
Apart from cleavage of the viral polyprotein, NS3 also 
cleaves a number of host molecules, which – at least in 
part – accounts for the high persistence rate in infected 
patients. For instance, NS3 inhibits important antiviral 
signaling pathways, including toll-like receptor 3-de-
pendent activation of interferon regulatory factor 3 by 
cleaving Toll/IL-1 receptor domain-containing adaptor 
inducing IFNβ and retinoic acid inducible gene I-medi-
ated activation of mitochondrial antiviral signaling pro-
tein. Both pathways are responsible for inducing antivi-
ral innate immune reactions in response to double-
stranded RNA, thus the presence of NS3 results in 
attenuated antivirus responses [5–7]. Besides reducing 
antiviral responses, NS3/4A also improves hepatocyte 
survival, and liver regeneration by enhancing nuclear 
factor κB activation that causes an increase in hepato-
protective TNFα, which is crucial for injury/inflamma-
tion-induced hepatocyte growth and liver regeneration 
[8, 9]. In addition, NS3/4A has been shown to cleave 
protein tyrosine phosphatase nonreceptor type 2 
(PTPN2, also known as T cell protein tyrosine phospha-
tase), and it has been suggested that high intrahepatic 
levels of NS3/4A are associated with low intrahepatic 
PTPN2 levels [10]. 
PTPN2 is an important immune modulator and loss-
of-function variants in the gene locus encoding PTPN2 
have been associated with a number of inflammatory dis-
orders, including inflammatory bowel disease, type I dia-
betes, psoriasis, and many others [11, 12]. Further, inac-
tivation of PTPN2 promotes hepatocellular carcinoma in 
a mouse model of nonalcoholic fatty liver disease [13], 
clearly showing the relevance of PTPN2 for liver health. 
On a molecular level, loss of PTPN2 results in exacerbat-
ed inflammatory responses [11, 14, 15]. Direct cellular 
targets of PTPN2 include Akt [16, 17], MAPK [17, 18], 
Jak/STAT signaling [19–24], and its loss results in attenu-
ated autophagosome formation [25]. Further, work by 
Brenndörfer et al. [26] indicates that NS3/4A cleaves 
PTPN2, resulting in a shift of the intrahepatic antiviral 
immune response toward a nonantiviral Th2-dominated 
immunity. Exacerbated Th2 responses are reverted by 
ribavirin, a drug-targeting HCV replication on several 
levels, such as improving the Th1/Th2 balance [27] by al-
tering the Th1/Th2 ratio toward a more antiviral Th1-
dominated immune response [28, 29]. This supports the 
theory that ribavirin complements the effects of DAAs as 
an immunomodulatory compound as it increases sus-
tained viral response rates, decreases viral breakthrough, 
and lowers relapse rates [30–33]. 
Liver injury in chronic HCV infected patients is 
thought to be a result of both the direct hepatotoxic effect 
of intrahepatic viral protein expression and tissue dam-
age induced by the host immune system [34]. Upon viral 
infection, cytotoxic T cells and NK cells directly attack 
virus-infected cells [35–37], resulting in a massive release 
of inflammatory cytokines [38] and eventually liver cell 
death. Cytokine and chemokine release is modulated by 
PTPN2 [26], and there is strong evidence that NS3 pro-
motes cytokine secretion via cleavage of PTPN2 [34, 38]. 
These findings suggest that intrahepatic PTPN2 levels 
might not only correlate with viral load but also with se-
rum levels of markers for liver damage, the presence of 
liver cirrhosis, or the Model of End-Stage Liver Disease 
(MELD) score. Based on those observations, we antici-
pate that intrahepatic PTPN2 levels might be useful as a 
predictive marker for DAA treatment success. Therefore, 
the aim of this study was to assess whether intrahepatic 
PTPN2 levels might serve as a prognostic marker for a 
response to DAA therapy.
Materials and Methods
Patients and Clinical Data
Liver tissue was obtained from patients undergoing routine liv-
er biopsy for staging of HCV-induced liver disease. All patients 
provided written informed consent. The study was approved by 
the Cantonal Ethics Committee of the Canton of Zurich (Ethical 
approval No EK-695).
Patient Characteristics
We retrospectively selected 27 patients from our large hepatitis 
C patient database for this study, 4 female and 23 male patients. 
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sponse to DAA therapy and presence of liver cirrhosis. Seven pa-
tients responded to DAA therapy and did not have liver cirrhosis, 
8 patients responded to DAA therapy but already had liver cirrho-
sis, and 12 patients did not respond to DAA therapy, meaning 
there was still measurable viral load after therapy. Liver biopsies 
were taken prior to therapy start. Clinical and serum markers, such 
as alanine aminotransferase, aspartate aminotransferase, gamma-
glutamyl transferase, and the MELD score and serum viral load 
were determined at the same time as the biopsy was collected. Ta-
ble 1 summarizes the baseline patient characteristics in each group. 
Control samples were obtained from 3 healthy liver donors (1 fe-
male, 2 males). 
PTPN2 Staining
In order to compare the intrahepatic PTPN2 levels of the dif-
ferent liver biopsies, we created a PTPN2 staining score (Fig. 1). 
Cytoplasmic staining was scored according to Figure 1 with “1” 
representing the lowest and “4” representing the highest intrahe-
patic PTPN2 level. Nuclear staining was scored according to the 
percentage of stained nuclei in relation to all nuclei of the hepato-
cytes.
Immunohistochemistry
After deparaffinization, tissue samples were incubated in 
 citrate buffer (pH 6.0, Dako, Agilent Technologies, Inc., 
 Santa Clara, CA, USA) for 30 min in a 98   ° C water bath. After 
cooling down to room temperature, slides were washed twice in 
phosphate-buffered saline (PBS, pH 7.2). To block endogenous 
peroxidases, slides were incubated for 15 min with 0.9% H2O2 
(Hänseler Swiss Pharma) in PBS. Unspecific binding sites were 
blocked by overnight incubation with 3% bovine serum albumin 
(BSA) in PBS in a humidified chamber at 4  ° C. Samples were then 
incubated with anti-PTPN2 antibody (PH03L-100UG, Merck, 
Darmstadt, Germany; clone Ab-1) at a concentration of 1.667 μg/
mL in 1% bovine serum albumin containing PBS for 3 h at room 
temperature in a humidified wet chamber, prior to washing 2 






Number 7 8 12
Gender, male, n (%) 5 (71) 6 (75) 11 (92)
Age, years, median (range) 58 (29–75) 57 (41–71) 52 (37–62)
Disease duration, median (range) 1.4 (0.1–27.4)1 16.8 (0.2–33.4)2 16.6 (0.4–33.8)3
Genotype, n (%)
1 5 (71) 4 (50) 4 (33)
2 1 (14) 1 (12.5) 1 (8)
3 1 (14) 1 (12.5) 3 (25)
4 0 2 (25) 4 (33)
DAA, n (%)
Sofosbuvir/ledipasvir 6 (86) 3 (37) 2 (17)
Sofosbuvir 1 (14) 5 (63) 10 (83)
Ribavirin received, n (%) 2 (29) 5 (63) 10 (83)
Metavir, n (%)
A1 5 (71) 3 (37) 7 (58)
A2 2 (29) 4 (50) 4 (33)
F1 3 (43) 0 0
F2 4 (57) 0 4 (33)
F3 0 1 (12) 3 (25)
F4 0 7 (88) 4 (33)
Ishak, n (%)
1 3 (43) 0 0
2 2 (29) 0 0
3 3 (29) 0 5 (42)
4 0 0 0
5 0 4 (50) 3 (25)
6 0 4 (50) 3 (25)
Cirrhosis present, n (%) 0 8 (100) 8 (67)
1 Data in 4/7 patients available.
2 Data in 5/8 patients available.













































































times in PBST (10 mM sodium phosphate, pH 7.5, 0.9% saline, 
0.1% Tween®-20). Samples were incubated with a horseradish 
peroxidase-labeled horse antimouse IgG solution (Vector Labo-
ratories) for 2 h at room temperature in a humidified wet cham-
ber and again washed 2 times in PBST. Staining was visualized 
using a DAB Peroxidase Substrate kit (Vector Laboratories, Peter-
borogh, UK). Samples were then counterstained with Haemalaun, 
dehydrated in ascending ethanol series and subsequently covered 
with Pertex® (Histolab Products AB). Microscopic assessment 
was done using an AxioCam HRc (Zeiss, Jena, Germany) on a 
Zeiss Axio Imager.Z2 microscope (Zeiss) with AxioVision Release 
4.8.2 software (Zeiss).
Statistical Analysis
Analysis of variance with Kruskal-Wallis post hoc test for sig-
nificance or spearman correlation where appropriate and as indi-
cated in the results section was performed using the GraphPad 
Prism Software and p values below 0.05 were considered signifi-
cant. 
Results
HCV Patients Nonresponding to DAA Therapy 
Exhibit Strong Cytoplasmic PTPN2 Staining in 
Hepatocytes
Based on the findings by Brenndörfer et al. [26], show-
ing direct cleavage of PTPN2 by the HCV NS protein NS3, 
we first aimed to investigate whether PTPN2 protein ex-
pression levels can serve as a clinical prognostic marker for 
the response to DAA therapy. For this aim, we stained liv-
er sections from HCV patients with liver cirrhosis that did 
respond to DAA therapy, patients without liver cirrhosis 
that responded to DAA therapy, and patients that did not 
respond to DAA therapy. In some patients, we observed 
very strong PTPN2 staining when compared to healthy 
controls (n = 3, all with a score of 2), while others showed 
weak or almost absent PTPN2 expression (Fig. 1). Of in-
Stained nuclei (red arrowhead) vs. non-stained nuclei (black arrowhead)
Healthy control
4 3 2 1
Stained cytoplasm








Fig. 1. Scoring of PTPN2 expression in liver biopsies. Paraffin-
embedded tissue from HCV infected human liver biopsies and 
healthy controls were stained for PTPN2 (brown). a PTPN2 stain-
ing in a healthy control. b Representative pictures for sections with 
a cytoplasmic staining score ranging from 1 to 4 with 1 represent-
ing the lowest cytoplasmic PTPN2 levels and 4 representing the 
highest levels. c Representative image showing nuclei with (red 
arrow) and nuclei without (black arrow) PTPN2 staining. Nuclear 
staining was scored according to the percentage of stained nuclei 
in relation to all nuclei (1 = 0–25%, 2 = 25–50%, 3 = 50–75%, 4 = 
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terest, in biopsies from healthy controls, nuclear staining 
of PTPN2 was almost completely absent (n = 3, all with a 
score of 1), while some patients showed enhanced nuclear 
staining (Fig. 1). Nevertheless, neither the nuclear nor the 
cytoplasmic staining score was significantly different be-
tween nonresponders, responders with cirrhosis and re-
sponders without liver cirrhosis (Fig. 2; p = 0.5662 and p = 
0.8271, respectively; Kruskal-Wallis test). However, when 
focusing on the cytoplasmic PTPN2 staining, the fraction 
of patients with a PTPN2 staining score of 2 or 3 indicating 
considerable PTPN2 levels in the cytoplasm was clearly 
higher in the nonresponder group than in responders with 
cirrhosis or responders without cirrhosis (91.7 vs. 62.5 vs. 
71.4% of patients of each respective patient subgroup). 
This suggests that patients with low cytoplasmic PTPN2 
protein might respond better to DAA therapy than pa-
tients with high cytoplasmic PTPN2 protein levels.
No Significant Correlation between Intrahepatic 
PTPN2 Levels and Viral Load
Since Brenndörfer et al. [26] clearly demonstrat-
ed that PTPN2 acts as a substrate for the viral NS3 pro-
tein, we next aimed to assess a possible correlation 
 between PTPN2 protein expression in the liver and 
 serum viral load, measured at the time of the liver bi-
opsies. Patients with a cytoplasmic PTPN2 staining 
score of 3 showed very high serum hepatitis C viral 
load. In contrast to the findings by Brenndörfer et al. 
[26], we did not observe a correlation between nuclear 
or cytoplasmic intrahepatic PTPN2 levels and viral load 
(Fig. 3; Spearman correlation, r = 0.0064, p = 0.976 and 
r = 0.334, p = 0.1193, respectively). However, patients 
with a cytoplasmic PTPN2 staining score of 3   always 



































































Fig. 2. PTPN2 staining does not correlate with liver cirrhosis or 
response to DAA therapy. Liver biopsies from responders to DAA 
therapy without cirrhosis (left), with cirrhosis (middle) and non-
responders (right) are plotted against the immunohistochemical 
staining of intrahepatic PTPN2 expression in (a) nuclei or (b) cy-
toplasm. Data shown as mean with 95% CI; Kruskal-Wallis test; 
p = 0.7099 (a) and p = 0.9298 (b); PTPN2, protein tyrosine phos-
phatase nonreceptor type 2.
a b PTPN2 nuclear staining score
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Fig. 3. PTPN2 staining levels do not corre-
late with viral load. Serum viral load at the 
time of liver biopsy collection was corre-
lated with the immunohistochemical stain-
ing score of intrahepatic PTPN2 expres-
sion in (a) the cytoplasm (r = –0.0064, p = 
0.976) and (b) nuclei (r = 0.334, p = 0.1193). 













































































No Correlation between Intrahepatic PTPN2 Levels 
and Clinical Markers
To further assess whether PTPN2 levels might serve 
as a prognostic marker for liver disease progression, we 
next studied whether intrahepatic PTPN2 levels 
 correlate with markers of liver injury. Therefore, we an-
alyzed mean serum levels of alanine aminotransferase, 
aspartate aminotransferase, gamma-glutamyl transfer-
ase, and the MELD score at the time of liver biopsy col-
lection and correlated them with the cytoplasmic or 
 nuclear PTPN2 IHC staining intensity. However, 
there was no significant correlation with any of these 
clinical markers of liver damage and intrahepatic 
PTPN2 expression as assessed by IHC (Fig. 4). Further-
more, there was no correlation between extent of liver 
































































































































Fig. 4. No correlation between MELD-
Score or markers for liver injury and 
PTPN2 expression levels. a, b MELD-
Score, (c, d) serum AST, (e, f) serum ALT, 
and (g, h) serum GGT were determined at 
the time of the liver biopsy and correlated 
with the immunohistochemical staining 
score of intrahepatic PTPN2 expression in 
cytoplasm (a, c, e, g) and nuclei (b, d, f, h). 
Spearman correlation revealed no correla-
tion between any of these factors with 
PTPN2 (r = –0.232 with p = 0.254 [a], 
r = –0.017 with p = 0.934 [b], r = 0.118 with 
p = 0.600 [c], r = 0.186 with p = 0.407 [d], 
r = –0.047 with p = 0.834 [e], r = 0.209 with 
p = 0.35 [f], r = –0.161 with p = 0.474 [g], 
r  = –0.083 with p = 0.7147 [h]). MELD-
score, the Model for End-Stage Liver Dis-
ease Score; PTPN2, protein tyrosine phos-
phatase nonreceptor type 2; AST, aspartate 
aminotransferase; ALT, alanine amino-
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VIR score of inflammation activity or fibrosis stage, re-
spectively, and nuclear or cytoplasmic PTPN2 expres-
sion (Fig. 5).
Discussion
In this study, we investigated whether PTPN2 staining 
of liver sections could serve as a predictive marker for re-
sponse to DAA therapy, or whether PTPN2 staining lev-
els correlate with viral load or clinical markers for liver 
failure. Our findings suggest that there is neither an obvi-
ous difference in intrahepatic PTPN2 levels between re-
sponders and nonresponders to DAA therapy nor did we 
detect a correlation between intrahepatic PTPN2 levels 
and viral load or clinical markers such as liver transami-
nases or the MELD score. 
The lack of a correlation between the amount of 
PTPN2 in liver cells and serum viral load is unexpected, 
since Rahbin et al. [10] previously demonstrated this con-
nection between intrahepatic PTPN2 levels and HCV vi-
ral load. Our study did not reproduce this finding, al-
though there was a clear trend toward a negative correla-
tion between PTPN2 and viral load. One possible 
explanation for the lack of a correlation might thus be the 
relatively small sample size. Furthermore, Rahbin et al. 
[10] investigated PTPN2 protein and mRNA levels in liv-
er biopsies using Western blot and qPCR, methods that 
do not distinguish expression levels in different cell types. 
In contrast, in our study, we investigated PTPN2 levels in 
biopsies using IHC. This allows assessment of PTPN2-
levels in a cell type specific manner as well as subcellular 
localization of PTPN2. In our staining score, we focused 
on PTPN2 staining intensity in hepatocytes and its sub-
cellular localization, where we could not detect signifi-
cant differences between the groups. Whole tissue analy-
ses in contrast reflect expression in all cell types, also im-
mune cells and fibroblasts, which express very different 
PTPN2 level as compared to hepatocytes. Therefore, the 
differences observed by Rahbin et al. [10] might reflect 
differences in cellular composition, rather than different 
PTPN2 expression in hepatocytes. Further, the cleavage 
of PTPN2 by NS3 might be a local phenomenon, and 
therefore hepatic PTPN2 levels might not reflect NS3 lev-
els or viral load in the serum. 
Other, more mechanistic studies published by the 
Bode group [16, 26, 39] showed that NS3/4A promotes 
secretion of chemokines and proinflammatory cytokines 
via cleavage of PTPN2, which acts as a negative regulator 
of these molecules. These studies also indicate that PTPN2 
cleavage by NS3/4 results in a shift from an antiviral Th1 
toward a Th2 immune response, finally promoting viral 
replication and persistence [26]. In contrast to those stud-
ies, our results suggest that viral activity/levels of NS3/4A 
do not correlate with PTPN2 levels. Also, the lack of a 
correlation between PTPN2 levels and response to DAA 
































































































Fig. 5. No correlation between METAVIR 
activity grade or fibrosis stage with nuclear 
or cytoplasmic PTPN2 expression levels. a, 
b METAVIR activity grade and (c, d) 
METAVIR fibrosis stage at the time of the 
liver biopsy were correlated with the im-
munohistochemical staining score of intra-
hepatic PTPN2 expression in cytoplasm (a, 
c) and nuclei (b, d). Spearman correlation 
revealed no correlation between these fac-
tors with PTPN2 (r = 0.0166 with p = 0.530 
[a], r = 0.0088 with p = 0.648 [b], r = 7.95 × 
10–5 with p = 0.9655 [c], r = 0.0215 with p = 
0.4749 [d]). PTPN2, protein tyrosine phos-
phatase nonreceptor type 2; AST, aspartate 
aminotransferase; ALT, alanine amino-













































































treatment suggests that the effect of DAA treatment on 
chemokine/cytokine levels, such as IP-10 and MIP-1β, is 
not dependent on an effect of DAA on PTPN2 protein 
levels. This is in line with findings by one of the studies of 
Brenndörfer et al. [26], which showed no difference in 
intrahepatic PTPN2 levels between mice subjected to 
Ribavarin therapy and untreated controls [26, 40]. 
Given the important role PTPN2 plays in controlling 
proinflammatory cytokine signaling, such as EGF-in-
duced signaling cascades and STAT molecules, and the 
role these cytokines play in liver damage in chronic HCV 
infection, we expected to observe a correlation between 
liver damage markers and PTPN2 levels. However, we 
could not detect any correlation between intrahepatic 
PTPN2 levels and markers for liver damage, cirrhosis, or 
MELD score. This is in line with previous study results 
where serum viral load did not correlate with the degree 
of liver injury [41–44], although we are unaware of any 
study that has tried to associate the MELD score with se-
rum HCV RNA before. Thus our data suggest that the 
intrahepatic PTPN2 levels, which might reflect intrahe-
patic, rather than serum NS3 levels [44], are not propor-
tional to the degree of liver injury or fibrosis.
The primary limitation of our preliminary analyses is 
clearly the small sample number, which prevents stratifi-
cation of our patient cohort into subgroups (e.g., accord-
ing to virus genotype or disease duration), which might 
mask potential effects. Nevertheless, our results are clear 
with regard to a very high variation of hepatocellular 
PTPN2 expression within the groups. Since healthy con-
trols did not show such a high variation, it might still be 
of interest to investigate the reason(s) for high versus low 
PTPN2 expression in HCV-infected patients.
Summarized, our results, in contrast to previously 
published reports on the effect of NS3/4A on PTPN2 ex-
pression and function in hepatocytes, demonstrate that 
assessment of intrahepatic PTPN2 levels using IHC stain-
ing does not represent a useful clinical prognostic marker 
for the response to DAA therapy.
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